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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not rolapitant 
is safe and effective in reducing the incidence of chemotherapy induced nausea and vomiting 
(CINV) in patients receiving emetogenic chemotherapy. 
 
Study Design: This review is based on three randomized controlled trials (RCTs) all published 
in 2015. The studies compared the safety and efficacy of rolapitant in decreasing the incidence of 
CINV. 
 
Data Sources: All articles used were published in English, in peer-reviewed journals, and found 
using PubMed and the Cochrane Review database. 
 
Outcomes Measured: All included studies measured the safety and efficacy of rolapitant on 
CINV. Specifically, studies evaluated incidence of emesis, use of rescue medications, and 
clinically significant nausea based on patient reporting in a study diary and answers to a study-
specific questionnaire. 
 
Results: Rapoport et al.1 found statistical significance (p = 0.032) in the effectiveness of 
rolapitant in reducing CINV in the overall phase. Rapoport et al.2 also found statistical 
significance of this (p = 0.0013) as well as Schwartzberg et al.3 (p = 0.0012). In the two studies 
conducted by Rapoport et al. it was found that rolapitant achieved statistical significance in 
achieving a CR in the acute, delayed, and overall phases. In Schwartzberg et al.3 rolapitant did 
not achieve a significant response in the acute phase but it did in the delayed phase. Overall 
rolapitant was well tolerated and any mild side effects were presumed to be a result of the 
underlying malignancy or the chemotherapy. 
 
Conclusions: Results of all 3 studies included indicate that prophylactic 180mg rolapitant is 
effective in reducing the incidence of CINV in patients receiving either moderately or highly 
emetogenic chemotherapy. Since all three studies used concomitant 5-HT3 receptor antagonists, 
further studies are warranted to prove the benefit of rolapitant as monotherapy. The question of 
the effectiveness of rolapitant as compared to others in its same class (NK-1 receptor 
antagonists) remains as well.  
 
Keywords: Rolapitant, chemotherapy. 
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INTRODUCTION 
Some patients may have risk factors that predispose them to the development of cancers 
but in reality, cancer can occur at any time and in any patient. It is well known that patients with 
a variety of different types of cancer will, at some point, be faced with the decision to undergo 
treatment with chemotherapy. Chemotherapy in itself carries negative stigma. This is probably 
because it is associated with cancer but can also be attributed to the many side effects that it can 
cause. Of the many side effects two of the most feared by patients are nausea and vomiting.4 
CINV is predicted to occur in up to 90% of patients receiving highly emetogenic chemotherapy.5 
When patients experience these symptoms they may seek treatment via family practice or 
possibly the emergency room if they develop significant complications such as dehydration.5 The 
point here is that this condition can be seen in many different settings and therefore becomes 
relevant to medical professionals in a variety of different practices. 
It is also relevant because it places a significant economical burden on healthcare. 
Different types of cancer affect countless patients each year and so, there is no shortage of 
patients receiving chemotherapy. In a study conducted by Burke, T. in 2011, it was found that 
more than one in eight patients had a follow-up hospital visit associated with CINV after 
receiving emetogenic chemotherapy. In this study the average cost of said follow up visit was 
$5,300.5 Although the exact number of hospital visits related to CINV is unknown, the study 
showed that 13.8% of patients receiving emetogenic chemotherapy experienced one or more 
CINV-associated hospital visit.5 
CINV remains prevalent due to its poorly understood mechanism. Some research exists 
and the most widely accepted theory is that chemotherapeutic drugs cause nausea and vomiting 
by activating neurotransmitter receptors in the small intestine; which stimulate the brainstem to 
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induce vomiting.7 Two receptors known to be involved in this pathway are the 5-HT receptor and 
NK-1 receptor.7 For this reason they are a major target of pharmacotherapy. 5-HT3 receptor 
antagonists such as granisetron and ondansetron have been valuable in treatment.6 NK-1 receptor 
antagonists such as aprepitant and fosaprepitant have been formulated more recently and have 
shown to provide more CINV prevention in the overall phase than 5-HT3 receptor antagonists.6 
Glucocorticoids, namely dexamethasone, have been evaluated and are used alone or in 
conjunction with 5-HT or NK-1 receptor antagonists.6 Over the past decade or so there have been 
advances in the medications used to treat CINV but it still remains prevalent even with the most 
recent therapeutic options.6 This is why rolapitant is being proposed as a new medication used to 
treat CINV. It is a NK-1 receptor antagonist with a much longer plasma half-life than either 
aprepitant or fosaprepitant.6 The hope is that this medication will be more effective in achieving 
complete control of CINV in patients who are being treated with highly or moderately 
emetogenic chemotherapy.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not rolapitant is 
safe and effective in reducing the incidence of chemotherapy induced nausea and vomiting 
(CINV) in patients receiving emetogenic chemotherapy.  
METHODS 
 Three double blind, randomized controlled trials were included in this systematic review.  
Studies were selected based on patient demographics, interventions used, comparisons made, and 
the outcomes that were measured. In all three studies patients were included if they were at least 
18 years of age and were scheduled to receive a first course of emetogenic chemotherapy. 
Schwartzberg et al.3 used patients who would be receiving moderately emetogenic chemotherapy 
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whereas both studies by Rapoport et al.1,2 included patients receiving highly emetogenic 
chemotherapy. In all three studies patients were given either one oral dose of 180mg rolapitant or 
visually matched placebo 2 hours prior to administration of emetogenic chemotherapy on day 1. 
Rapoport et al.1 gave all patients 32mg IV ondansetron and 20mg oral dexamethasone 30 
minutes before initiation of chemotherapy on day 1 and 8mg dexamethasone twice daily on days 
2-4. Rapoport et al.2 gave all patients 10 µg/kg IV granisetron and 20mg oral dexamethasone on 
day 1, and 8mg oral dexamethasone twice daily on days 2-4. Schwartzberg et al.3 gave all 
patients 2mg oral granisetron and 20mg oral dexamethasone on day 1 and 2mg oral granisetron 
on days 2 and 3. The outcome measured in all studies was the percentage of patients achieving a 
complete response (CR) in the overall phase (0-120h), where CR is defined as no vomiting or 
use of rescue medication.  
 I researched PubMed and the Cochrane Database for all articles included in this study. 
Key words used in my searches included “rolapitant” and “chemotherapy.” Articles needed to 
meet certain criteria in order to be selected for the study. All articles included were published in 
peer-reviewed journals in 2015 in English. Articles were included if they demonstrated outcomes 
beneficial to patients (POEMs) and if they were double blind RCTs with matched placebo. 
Articles were excluded if the dose of rolapitant was not 180mg. All studies included used 
statistical analysis on their data including p-values and confidence intervals.   
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Table 01. Demographics and Characteristics of Included Studies 
Study Type # of 
Pts 
Age 
(years) 
Inclusion 
Criteria 
Exclusion 
Criteria W/D Interventions 
Rapoport, 
2015 (1) 
RCT 181 20-77 Patients ≥18 
years 
scheduled to 
receive highly 
emetogenic 
chemotherapy; 
Karnofsky 
performance 
score of 60 or 
more 
Patients with 
ongoing 
vomiting; that 
had previously 
received 
cisplatin or 
were planning 
to receive 
cisplatin; taking 
other drugs that 
could interfere 
with the study 
(corticosteroids) 
14 180mg oral 
rolapitant vs. 
visually 
matched 
placebo 
Rapoport, 
2015 (2) 
RCT 532 20-90 Patients ≥18 
years old 
scheduled to 
receive 
cisplatin-
based 
chemotherapy; 
Karnofsky 
performance 
score of 60 or 
more 
Patients with 
ongoing 
vomiting; 
current medical 
condition other 
than malignant 
disease that 
would confound 
the results of 
the study or 
pose risk to the 
patient; 
previous use of 
cisplatin or 
planning to 
receive cisplatin 
6 180mg oral 
rolapitant vs. 
visually 
matched 
placebo 
Schwartz-
berg, 
2015 (3) 
RCT 1,332 22-88 Patients ≥18 
years old 
scheduled to 
receive a first 
course of 
moderately 
emetogenic 
chemotherapy; 
Karnofsky 
performance 
score of 60 or 
more 
Patients with 
ongoing 
vomiting; 
current medical 
condition other 
than malignant 
disease that 
would confound 
the results of 
the study or 
pose risk to the 
patient; 
previous/current 
use of cisplatin 
68 180mg oral 
rolapitant vs. 
visually 
matched 
placebo 
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OUTCOMES MEASURED 
 Outcomes that were significant endpoints to all studies include incidence of emesis, use 
of rescue medications, and clinically significant nausea. All 3 of the included studies measured 
their outcomes in the same manner. All events of nausea, emesis, or use of rescue medications 
were recorded in each patient’s study diary for the first 120 hours of cycle 1. Nausea was 
measured on a 100-mm horizontal 10-point visual analog scale (VAS) with clinically significant 
nausea being defined as >25mm. The Functional Living Index-Emesis (FLIE) questionnaire was 
used to determine the impact of CINV on patient daily living. This included 9 questions on both 
nausea and vomiting, which were on a 7-point VAS. Any score >108 was defined as having no 
effect on daily living.  
 Safety was another endpoint of all studies included. In all three studies safety was 
assessed based on clinical review of adverse events reported by patients. When a patient reported 
any adverse event patients received a work-up including vital signs, physical examination, 
electrocardiogram, and other clinically relevant lab value readings.  
RESULTS 
All three studies were conducted using the methods outlines previously. In Rapoport et 
al.1 454 patients were treated with rolapitant (or placebo) at varying doses. Doses of 9mg, 
22.5mg, 90mg, and 180mg were administered. All patients were randomly assigned to treatment 
groups. 90 total patients were given 180mg rolapitant vs. 91 patients who received placebo. In 
this study most patients were male by chance. 38 patients withdrew from the study most 
commonly due to adverse events. In Rapoport et al.2, 526 patients (264 rolapitant and 262 active 
control) were randomized into two treatment groups which received either 180mg rolapitant or 
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placebo. This study, like the first, included more males than females by chance and the most 
common primary malignancy was lung cancer. 25 patients withdrew from the study most 
commonly due to withdrawal of consent. In Schwartzberg et al.3, 1,332 patients were randomly 
assigned into two treatment groups. The groups received either 180mg rolapitant or placebo. In 
this study, patients were mostly women with a primary malignancy of breast cancer. 34 patients 
withdrew from each treatment group. Withdrawal of consent was the most common reason. 
Efficacy of Rolapitant 
 In all three of the included studies, the efficacy of rolapitant was proven to be statistically 
significant as compared to placebo in achieving a complete response in the overall phase. These 
data are highlighted below by Table 02. 
Table 02. Efficacy of Rolapitant on CINV in the Overall Phase 
Study 
Intervention (% of pts with CR) Odds Ratio 
(95% CI) p-value Rolapitant 180mg Active Control 
Rapoport et al.1 62.50% 46.70% NA 0.032 
Rapoport et al.2 70% 56% 1.8 (1.3-2.6) 0.0013 
Schwartzberg et al.3 62% 53% 1.4 (1.2-1.8)  0.0012 
 
In Rapoport et al.1 the primary endpoint of the study was those patients receiving a CR in 
the overall phase. They also measured CR in the acute phase (0-24h) and the delayed phase (24-
120h). Rolapitant was more effective than placebo in achieving a CR in all three phases. 
Furthermore, patients who received 180mg of rolapitant had greater rates of no emesis or 
significant nausea and overall fewer patients required the use of rescue medications in the acute, 
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delayed, and overall phases as compared to placebo. Through use of the FLIE questionnaire it 
was also determined that patients who received 90mg and 180mg rolapitant had significantly 
improved quality of life as compared to placebo. 
In Rapoport et al.2 the primary endpoint of the study was those patients receiving a CR in 
the delayed phase (24-120h). They also measured CR in the acute phase (0-24h) and the overall 
phase (0-120h). Rolapitant was more effective than placebo in achieving a CR in all three 
phases. When comparing results of the acute phase CR and delayed phase CR it was discovered 
that there was a correlation of CR in acute and delayed phases. If a patient had a CR in the acute 
phase that patient was more likely to continue to achieve a CR within the delayed phase as well.  
In Schwartzberg et al.3 the primary endpoint of the study was those patients receiving a 
CR in the delayed phase (24-120h). Patients in the rolapitant study group achieved a significantly 
greater rate of CR in the delayed phase as compared to placebo. They also measured CR in the 
acute phase (0-24h) and the overall phase (0-120h). Rolapitant was more effective than placebo 
in achieving a CR in the overall phase but in the acute phase there was no significant difference. 
In patients who did not need rescue medication or vomit within the first 48 hours, they were 
more likely to remain protected in the overall phase as compared to placebo. 
Each individual study proved the efficacy of rolapitant in achieving a CR in the overall 
phase. The number needed to treat (NNT) was determined for each individual study and then 
converted into one final NNT relevant to the data for all 3 studies. This final NNT came to 7. 
These data are displayed below in table 03.  
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Table 03. Efficacy of Rolapitant on CINV: NNT 
% of patients 
with CR on 
placebo 
% of patients 
with CR on 
rolapitant 
Relative risk 
reduction (RRR) 
Absolute risk 
reduction (ARR) 
Number needed 
to treat (NNT)  
CER EER 
EER – CER 
EER - CER 1/ARR CER 
53.6% 67.2% 25.4% 13.6% 7 
 
Safety of Rolapitant 
 In Rapoport et al.1 there were incidences of both mild and severe adverse events (AE) 
The mild AEs were dizziness, headache, constipation, and fatigue. Serious AEs occurred in 11% 
of patients and included nausea, vomiting, dehydration, febrile neutropenia, neutropenia, 
pneumonia and renal failure. AEs occurred equally amongst all treatment groups and were most 
likely due to underlying progression of malignancy or the chemotherapy itself. 12 deaths 
occurred in patients during this study, which were all attributed to cancer progression or 
chemotherapy.  In Rapoport et al.2 the incidence of AEs was randomly split between the 
rolapitant study group and the placebo study group. The most common AEs included headache, 
dyspepsia, constipation, and hiccups. There were no treatment related deaths amongst either 
study group. In Schwartzberg et al.3 the incidence of AEs was randomly split between the 
rolapitant study group and the placebo study group. The most common AEs included dizziness, 
headache, constipation, and, fatigue. There were few incidences of neutropenia and febrile 
neutropenia across both study groups but there were no treatment related deaths amongst either 
study group. 
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Table 04. Common Mild Adverse Events Organized by Study 
  Adverse Event   
Rapoport et al.1 Rapoport et al.2 Schwartzberg et al.3 
dizziness headache dizziness 
headache dyspepsia headache 
constipation constipation constipation 
fatigue hiccups fatigue 
 
DISCUSSION 
 In all three studies rolapitant achieved statistical significance in reducing the incidence of 
CINV in the overall and delayed phases. In the acute phase this was true of both studies done by 
Rapoport et al. but Schwartzberg could not prove this. It was also true of two studies, Rapoport 
et al.2 and Schwartzberg et al.3, that when patients achieved a CR in the acute phase they were 
more likely to continue to achieve a CR in the overall phase. This could indicate that preventing 
CINV in patients acutely could help to eliminate it in the overall phase as well.  
 Rolapitant has known drug interactions that can limit its use. Since the liver metabolizes 
it, it is also limited in those patients with significantly decreased liver function.7 It can still be 
given if need be, but those patients need to be carefully monitored throughout therapy.7 
 The most common AEs during treatment were mild and included constipation, fatigue, 
headache, and dizziness. Patients tolerated these side effects well. It was supposed that most of 
the AEs were a result of worsening underlying disease or the chemotherapy treatment. There 
were a number of deaths across all studies but none that could be contributed to treatment with 
rolapitant.  
One of the main limitations of my search was that rolapitant has been very minimally 
studied. Therefore, the number of studies fitting my criteria was few. All of the studies included 
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had some of the same authors involved and also had virtually identical study designs. It may 
have been helpful to have different methods used in order to get a better understanding of how 
effective rolapitant can be in different patient populations as well as in combination with 
different concomitant therapies. A limitation common to all three studies was the use of 
concomitant 5-HT3 receptor antagonists. Rolapitant was proven to be more beneficial in 
achieving a CR than using a 5-HT3 receptor antagonist alone. Now, the question remains; would 
rolapitant still be as effective without concomitant use of a 5-HT3 receptor antagonist? 
CONCLUSION 
 This systematic review indicates that rolapitant can be used to achieve significantly 
greater relief from CINV in patients receiving either moderately or highly emetogenic 
chemotherapy. In all three studies patients received a CR in the overall phase meaning that they 
were adequately protected from CINV the entire time they were at risk. Patients experienced 
some mild side effects but it was not discernable if this was due to rolapitant. It was presumed 
that rolapitant was well tolerated in all individuals and that patients suffered side effects from 
either their cancer or the chemotherapy. Future studies should be focused on the efficacy of 
rolapitant without concomitant 5-HT3 receptor antagonists. It is true that rolapitant offers better 
overall protection from CINV but it should be tested alone. If this were done it could lessen the 
pharmacologic burden on patients. Rolapitant should also be tested alongside other NK-1 
receptor antagonists to prove its efficacy as compared to other medications in the same class. 
Limitations aside, it has still been shown that rolapitant is a step in the right direction for the 
improvement of CINV.   
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